Real-world data in 1477 patients on dialysis show tenapanor reduced serum phosphate at 6 months with or without background phosphate binders.
|Articles|September 16, 2008
- February29 2004
- Volume 11
- Issue 4
Offbeat Market Indicators
Author(s)Michael Sheehan
Advertisement
Time
Time
Want to know where the market isheaded this year? Traditional marketmavens will tell you to watch the market'sJanuary numbers. An up-month usuallyprefigures positive results for theyear. Others look at quirkier signals, likethe height of women's hemlines or thecover of magazine. The Super Bowlindicator, which predicts an up-year forthe market when the NFC team or a teamfrom the old NFL wins, was on target lastyear, raising its batting average to about90%. Hemlines are up, which also augursanother year of rising stock prices. Watchout, though, if features the currentbull market on its cover. ConventionalWall Street wisdom says that by the timethe general media get wind of a financialtrend, it's usually over.
Articles in this issue
about 18 years ago
Choose Wisely when Managing Your Debtsabout 18 years ago
Avoid the Problems with Switching Banksabout 18 years ago
Be a Thoughtful and Caring Grandparentabout 18 years ago
Teach Financial Skills to Your Childrenabout 18 years ago
Safeguard Yourself from Identity Theftabout 18 years ago
Happiness, Elusive, but Somewhere Out Thereabout 18 years ago
Fund Fundamentalsabout 18 years ago
Diversified Portfoliosabout 18 years ago
Doing Some Flipsabout 18 years ago
Beefed-Up 401(k)sAdvertisement
Related to this article
Approval rests on the phase 3 AFFIRM trial, in which 56% of patients reached clinical remission at week 12 vs 30% with placebo.
Jean Elwing, MD, discusses what drove ralinepag's reduction in PAH clinical worsening in ADVANCE Outcomes and where the it could fit if approved.
Jean Elwing, MD, discusses a CHEST 2026 subgroup analysis showing ralinepag reduces clinical worsening in PAH even among patients with low-risk criteria.
Participants described earlier phenotyping, closer tracking of steroid exposure, and recognizing gradual gains on biologic therapy.
Interim IMAgINATION data show the once-monthly factor B antisense therapy sefaxersen reduced proteinuria by 43.1% vs placebo at week 37 in IgA nephropathy.
Interim RAINIER data show povetacicept reduced proteinuria by 52.0% and resolved hematuria in 85% of patients at week 36, ahead of a November PDUFA date.
Interim I CAN data show ravulizumab reduced proteinuria by 43.4% vs placebo at week 34, supporting its FDA accelerated approval in IgA nephropathy.
Advertisement
Advertisement
Trending on HCPLive
1
Retatrutide Lowers Albuminuria, Glomerular Pressure in Obesity and CKD
2
Sleeve Gastrectomy Improves Heart, Kidney MRI Markers in Youth-Onset T2D
3
TELIGAN: Telitacicept Preserves eGFR Through 2 Years in IgA Nephropathy
4
Ravulizumab Receives FDA Accelerated Approval for IgA Nephropathy
5